P&G pharma sale may take time

The credit crunch could force Procter & Gamble to hang onto its pharma unit longer than it wants to, analysts say. In fact, selling off the $2.2 billion pharmaceutical division might have to wait until 2010.

"I'd be surprised if there was a deal this year," Pete Sorrentino, vice president and senior portfolio manager at Huntington Asset Advisors told the Cincinnati Business Courier. "The people who might look at it are saying, 'It ain't going anywhere, we'll get back to that.'"

Part of the problem in attracting a buyer, however, doesn't have anything to do with the credit markets. P&G's biggest drugs--the bone drug Actonel and colitis treatment Asacol--haven't been blowing sales out of the box lately. And the products that are more promising are either still awaiting FDA approval, or they're tied up in external marketing agreements.

- see the Courier story

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.